Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Gilotra NA, DeVore AD, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E, on behalf of the LIFE Investigators
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial
J Am Coll Cardiol HF 2020;8:789-99.
The following sentence should have been included: “Novartis Pharmaceuticals Corporation is providing the study drug and partial funding through the Investigator Initiated Trial (IIT) program (CLCZ696BUS04T).”
The Authors apologize for this error.